sarcosine has been researched along with Dementia in 5 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsai, CH | 1 |
| Huang, HC | 1 |
| Liu, BL | 1 |
| Li, CI | 1 |
| Lu, MK | 1 |
| Chen, X | 1 |
| Tsai, MC | 1 |
| Yang, YW | 1 |
| Lane, HY | 1 |
| Spillantini, MG | 3 |
| Crowther, RA | 3 |
| Kamphorst, W | 1 |
| Heutink, P | 1 |
| van Swieten, JC | 1 |
| Hulette, CM | 1 |
| Pericak-Vance, MA | 1 |
| Roses, AD | 1 |
| Schmechel, DE | 1 |
| Yamaoka, LH | 1 |
| Gaskell, PC | 1 |
| Welsh-Bohmer, KA | 1 |
| Yasuda, M | 1 |
| Takamatsu, J | 1 |
| D'Souza, I | 1 |
| Kawamata, T | 1 |
| Hasegawa, M | 2 |
| Hasegawa, H | 1 |
| Tanimukai, S | 1 |
| Poorkaj, P | 1 |
| Varani, L | 1 |
| Varani, G | 1 |
| Iwatsubo, T | 2 |
| Goedert, M | 1 |
| Schellenberg, DG | 1 |
| Tanaka, C | 1 |
| Hayashi, S | 1 |
| Toyoshima, Y | 1 |
| Umeda, Y | 1 |
| Wakabayashi, K | 1 |
| Tokiguchi, S | 1 |
| Takahashi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01785628] | 30 participants (Actual) | Interventional | 2010-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The BDI-II is a 21-item self-report questionnaire assessing the current severity of depression symptoms. Each item is scored on a scale of 0 to 3 and the total score ranges from 0 to 63. With a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | V1(2 weeks) | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 9.9 | 10.5 | 10.2 | 9.8 |
| Sarcosine Capsule | 14.3 | 15.6 | 15.8 | 17.5 |
The Behave-AD includes the assessment of symptoms and a global rating of caregiver distress. A total of 25 symptoms in 7 clusters are rated: paranoid and delusional ideation, hallucinations, aggressiveness, activity disturbances, diurnal rhythm disturbances, affective disturbances and anxieties, and phobias. Caregivers rate behavioral symptoms over the preceding 2 weeks on a 0 to 3 scale. The caregiver also determines a global assessment of caregiver distress on a scale of 0 to 3. The maximum score is 75 and with a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | V1(2 weeks) | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 7.9 | 5.2 | 6.8 | 6.4 |
| Sarcosine Capsule | 10.0 | 8.4 | 7.5 | 9.4 |
The CDR is a 5-point scale used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment & Problem Solving, Community Affairs, Home & Hobbies, and Personal Care. With a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 1.1 | 1.1 | 1.1 |
| Sarcosine Capsule | 2.3 | 2.1 | 2.0 |
The Cognitive Abilities Screening Instrument (CASI) has a score range of 0 to 100 and provides quantitative assessment on attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency, abstraction, and judgment. With a higher score indicating Symptom improvement. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline | V2(4 weeks) | V3(8weeks) | |
| Placebo Capsule | 63.9 | 63.9 | 63.9 |
| Sarcosine Capsule | 50.9 | 53.1 | 52.4 |
The HAM-D is a 21-item rating scaled which includes an emphasis on behavioral symptoms and somatic complaints that neglects self-reported feelings of distress; and an intermingling of frequency and intensity of symptoms. The total score ranges from 0 to 64: ten items are ranked on a scale from 0 to 4; 9 items are ranked 0 to 2; and 2 items are ranked 0 to 3. With a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | V1(2 weeks) | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 7.6 | 7.6 | 7.8 | 7.3 |
| Sarcosine Capsule | 11.8 | 9.9 | 10.1 | 11.0 |
The NPI scale has 12 domains: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. The total score ranges from 0 to 144, where the score for a domain is defined as the product of frequency (range: 1-4) and severity (range: 1-3). Each domain has a maximum score of 12 and with a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | V1(2weeks) | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 14.9 | 14.1 | 11.7 | 13.3 |
| Sarcosine Capsule | 18.4 | 14.8 | 12.4 | 18.1 |
The PDQ-39 contains 39-items covering 8 discrete dimensions: mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort. Each question is scored on a 5-point scale and recoded to 0 to 4 for the analysis. The total score can range from 0 to 132 and with a higher score indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | V1(2 weeks) | V2(4 weeks) | V3(8 weeks) | |
| Placebo Capsule | 64.8 | 60.9 | 60.9 | 60.1 |
| Sarcosine Capsule | 68.0 | 67.9 | 65.9 | 63.7 |
Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline to 8 weeks. The UPDRS score has three parts, part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living) and Part III (Motor Examination). Each consisting of questions answered on a 0-4 point scale. The minimum total score possible is 0 and the maximum total score possible is 176. Higher scores indicating more severe symptoms. (NCT01785628)
Timeframe: baseline to 8 weeks.
| Intervention | Scores on a scale (Mean) | |||
|---|---|---|---|---|
| baseline | V1(2-week) | V2(4-week) | V3(8-week) | |
| Placebo Capsule | 66.7 | 65.2 | 67.6 | 68.3 |
| Sarcosine Capsule | 71.6 | 67.9 | 69.3 | 71.3 |
1 trial available for sarcosine and Dementia
| Article | Year |
|---|---|
Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia.
Topics: Aged; Aged, 80 and over; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson | 2014 |
4 other studies available for sarcosine and Dementia
| Article | Year |
|---|---|
Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau.
Topics: Aged; Aged, 80 and over; Chromosomes, Human, Pair 17; Dementia; Detergents; Exons; Frontal Lobe; Hip | 1998 |
Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21-22 (FTDP-17): Duke Family 1684.
Topics: Adult; Age of Onset; Aged; Chromosomes, Human, Pair 17; Dementia; Female; Frontal Lobe; Humans; Immu | 1999 |
A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto)
Topics: Brain; Brain Chemistry; Dementia; Detergents; DNA Mutational Analysis; Exons; Family Health; Female; | 2000 |
Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation.
Topics: Age of Onset; Aged; Aged, 80 and over; Dementia; Detergents; Exons; Humans; Inclusion Bodies; Male; | 2002 |